All In Biotech

Drug Trial Radar · NCT06819007

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 582 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

582

Planned (sponsor's estimate)

Start

Mar 19, 2025

Primary completion

Nov 1, 2028

Study completion Jan 31, 2032

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W).

  • BevacizumabDrug

    Bevacizumab will be administered at a dose of 15 mg/kg IV Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ PopulationTime frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months

Locations

232 sites in 26 countries. Site status is shown where the registry gives one.

  • Disney Family Cancer Center

    Burbank, California · Recruiting

  • Scripps Clinic

    La Jolla, California · Recruiting

  • Palo Alto Medical Foundation

    Palo Alto, California · Recruiting

  • Broward Health Medical Center

    Fort Lauderdale, Florida · Recruiting

  • Jupiter Medical Center

    Jupiter, Florida · Recruiting

  • Mount Sinai Medical Center

    Miami Beach, Florida · Recruiting

  • AdventHealth Cancer Institute

    Orlando, Florida · Recruiting

  • Woman's Care FL

    St. Petersburg, Florida · Recruiting

  • Nancy N. & J.C Lewis Cancer & Research Pavillion- St. Josephs/ Candler Health System

    Savannah, Georgia · Recruiting

  • Endeavor Health Evanston Kellogg Cancer Care Center

    Evanston, Illinois · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • Trials365 LLC

    Shreveport, Louisiana · Recruiting

  • Greater Baltimore Medical Center

    Towson, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Trinity Health St. Joseph Mercy Ann Arbor

    Ann Arbor, Michigan · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Recruiting

  • Minnesota Oncology Hematology PA

    Minneapolis, Minnesota · Recruiting

  • St. Vincent Gynecologic Oncology

    Billings, Montana · Recruiting

  • Valley Health System

    Paramus, New Jersey · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • UNC Hospital

    Chapel Hill, North Carolina · Recruiting

  • Miami Valley Hospital South

    Centerville, Ohio · Recruiting

  • Legacy Medical Group Gynecologic Oncology

    Portland, Oregon · Recruiting

  • Providence Cancer Center Oncology

    Portland, Oregon · Recruiting

  • St. Lukes University Health Network

    Bethlehem, Pennsylvania · Recruiting

  • Ann B Barshinger Cancer Institute

    Lancaster, Pennsylvania · Recruiting

  • Avera Medical Group Gynecologic

    Sioux Falls, South Dakota · Recruiting

  • Sarah Cannon Research Institute (Oncology Associates of Oregon PC)

    Nashville, Tennessee · Recruiting

  • Utah Cancer Specialists Network

    Salt Lake City, Utah · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Genesiscare St Andrews Hospital

    Adelaide, Australia · Recruiting

  • Icon Cancer Centre Wesley

    Auchenflower, Australia · Recruiting

  • Icon Cancer Centre Hobart

    Hobart, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Perth, Australia · Recruiting

  • Epworth Healthcare

    Richmond, Australia · Recruiting

  • Genesis Care North Shore (Oncology)

    St Leonards, Australia · Recruiting

  • Westmead Hospital

    Sydney, Australia · Recruiting

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.